Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Live attenuated oral Salmonella platform for effective T- and B-cell targeting of PD-L1.
Authors
Sébastien Wieckowski
VAXIMM AG, Basel, Switzerland
Sébastien Wieckowski, Heiko Smetak, Iris Kobl, Lilli Podola, Anne-Lucie Nugues, Philippe Slos, Amine Adda Berkane, Ming Wei, Klaus M. Breiner, Albrecht Meichle, Marc Mansour, Matthias Schroff, Philipp Beckhove, Heinz Lubenau
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies
Sub Track
Vaccines and Oncolytic Viruses
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr 74)
DOI
10.1200/JCO.2018.36.5_suppl.74
Abstract #
74
Poster Bd #
F1
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50%.
First Author: Melissa Lynne Johnson
Poster
2023 ASCO Annual Meeting
Investigation into aberrant B cell repertoire in myeloma on humoral immunity and patient survival.
First Author: Lakshmi Bhavani Potluri
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase I trial of perioperative chemotherapy plus immunotherapy in localized esophageal and gastroesophageal adenocarcinoma.
First Author: Mariela A. Blum Murphy
Poster
2022 ASCO Annual Meeting
Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC.
First Author: Aaron E. Lisberg